A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Slovenia- Participants:18–64 years
Rare diseases
Investigational molecules
Locations
SloveniaA Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
SloveniaA study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time
SloveniaA Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread
Slovenia
SloveniaStudy on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
SloveniaStudy on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy
SloveniaA study to evaluate the effectiveness of bleomycin sulfate for treating patients with low-flow vascular malformations using electrosclerotherapy.
SloveniaA study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
SloveniaA study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy
Slovenia
SloveniaA Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
SloveniaTell us about your condition – we search every trial in Europe and connect you with the right site.